The 1988 launch of Prozac marked a major shift in pharmaceutical branding. Its name was a non-descriptive "empty vessel" designed for marketing impact ('pro' for positive, 'zac' for energy), moving away from names that explained a drug's function.

To find an original name, don't just look within your industry. Explore diverse domains like mythology, science, or aerodynamics. The goal is to map out a wide 'ocean' of possibilities before diving in, ensuring you discover unique concepts instead of defaulting to industry jargon.

Don't censor ideas early. The path to innovative marketing is generating a high volume of unconventional, even "bad," ideas. Most will fail, but the one or two that succeed can become massive multipliers for your brand, often requiring you to ask for forgiveness, not permission.

The FDA's strict guidelines against look-alike/sound-alike names (to prevent prescription errors) and names that over-promise a cure are the primary drivers behind the seemingly strange, unique, and often sci-fi-sounding spellings of modern pharmaceutical brands.

To avoid groupthink, assign teams varied briefs for the same project. One team gets the core details, another adds a conceptual ingredient like 'energy,' and a third reframes the product in a new category like 'athletic performance.' This produces distinct types of names.

The path to a great name is paved with mediocre ones. The key is embracing quantity to find quality. Teams that stop after generating only 50-100 names get stuck, whereas a professional process might explore over 2,000 possibilities to uncover a true gem.

Instead of traditional, costly focus groups, founders can leverage Large Language Models (LLMs) to conduct "synthetic research." These tools can simulate consumer reactions to brand names, providing rapid, low-cost feedback to guide decision-making.

To prevent errors from illegible handwriting, the FDA favors drug names with a varied visual shape, created by using letters that ascend (b, d, h) and descend (g, p, y). This typographical safety consideration is a key, non-obvious factor in a name's approval.

Unlike consumer-facing drugs, many cancer therapies have names derived from their scientific mechanism of action. This is a deliberate strategy to communicate the drug's uniqueness and resonate with the true target audience: oncologists who understand the science.